Standard Biotools (LAB) Amortization of Deferred Charges (2017 - 2023)

Standard Biotools (LAB) has 7 years of Amortization of Deferred Charges data on file, last reported at $173000.0 in Q4 2023.

• Amortization of Deferred Charges for Q4 2023 came in at $173000.0, down 14.36% year-over-year; the trailing twelve-month figure through Dec 2023 was $770000.0 (down 7.23% YoY), and the FY2023 annual result was $770000.0, down 7.23% from the prior year.
• Amortization of Deferred Charges slipped to $173000.0 in Q4 2023 per LAB's latest filing, from $187000.0 in the prior quarter.
• Over five years, Amortization of Deferred Charges peaked at $2.0 million in Q1 2019 and troughed at -$194000.0 in Q4 2019.
• A 5-year average of $269500.0 and a median of $194500.0 in 2022 frame the typical range for Amortization of Deferred Charges.
• The sharpest annual moves came in 2019 and 2021: Amortization of Deferred Charges slumped 107.28% in 2019, then jumped 205.0% in 2021.
• A 5-year view of Amortization of Deferred Charges shows it stood at -$194000.0 in 2019, then jumped by 167.01% to $130000.0 in 2020, then soared by 228.46% to $427000.0 in 2021, then sank by 52.69% to $202000.0 in 2022, then decreased by 14.36% to $173000.0 in 2023.
• Business Quant data shows LAB's Amortization of Deferred Charges at $173000.0 in Q4 2023, $187000.0 in Q3 2023, and $206000.0 in Q2 2023.